Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBT-107
- Development stage
- Preclinical
- Lead developer
- Cellective BioTherapy
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
CBT-107 is a preclinical-stage monoclonal antibody being developed by Cellective BioTherapy for the treatment of oncology indications. The therapeutic is designed to deplete regulatory B10 cells (IL-10-producing regulatory B cells), which are known to suppress anti-tumor immune responses. By depleting these regulatory B cells, CBT-107 aims to enhance the body's natural immune response against tumors. CBT-107 is being developed for use in combination with immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to achieve synergistic anti-tumor efficacy.
Beyond the preview
Go deeper on CBT-107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CBT-107.